Search results
Results from the WOW.Com Content Network
The U.S. Food and Drug Administration has approved InterStim Therapy, by Medtronic, as a sacral nerve stimulator for treatment of urinary incontinence, high urinary frequency and urinary retention. Sacral nerve stimulation is also under investigation as treatment for other conditions, including constipation brought on by nerve damage due to ...
Percutaneous tibial nerve stimulation (PTNS), also referred to as posterior tibial nerve stimulation, is the least invasive form of neuromodulation used to treat overactive bladder (OAB) and the associated symptoms of urinary urgency, urinary frequency and urge incontinence.
The dispute centers on Medtronic's InterStim device, an implanted neurostuimulator used to treat patients with an overactive bladder and bowel-control conditions. On Thursday, Medtronic filed a ...
Intraoperative magnetic resonance imaging (iMRI) is an operating room configuration that enables surgeons to image the patient via an MRI scanner while the patient is undergoing surgery, particularly brain surgery. iMRI reduces the risk of damaging critical parts of the brain and helps confirm that the surgery was successful or if additional resection is needed before the patient's head is ...
Medtronic operational headquarters in Fridley, Minnesota, a suburb of Minneapolis. Medtronic was founded in 1949 in Minneapolis by Earl Bakken and his brother-in-law, Palmer Hermundslie, as a medical equipment repair shop. [8] Bakken invented several medical technology devices that continue to be used around the world today. [citation needed]
Urinary diversion is a surgical technique used to create a new pathway for urine to exit the body, often following the removal of the bladder as part of treatment for bladder cancer. [1] In addition to bladder cancer, urinary diversion may be necessary in cases of severe trauma, congenital abnormalities, or other conditions that compromise the ...
difficulties emptying the bladder requiring temporary self-catheterization; persistent stress urinary incontinence; infection of the device leading to removal; recurrent incontinence from either device failure or atrophy of the urethral tissues (in which case further surgery can remove the old device and replace it with a new one).
Risks of bladder augmentation include incomplete voiding of the bladder post-surgery (resulting in the patient having to undergo intermittent catheterisation or receive an indwelling catheter), acute intestinal obstruction due to adhesions some years after surgery, and, in extremely rare cases, cancers of the intestinal tissue within the bladder.